Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$15M—

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's contingent consideration fair value adjustments?
Cumberland Pharmaceuticals (CPIX) reported contingent consideration fair value adjustments of -$228.97K in Q1 2026.
How has Cumberland Pharmaceuticals's contingent consideration fair value adjustments changed year-over-year?
Cumberland Pharmaceuticals's contingent consideration fair value adjustments decreased by 609.1% year-over-year, from $44.98K to -$228.97K.
What is the long-term trend for Cumberland Pharmaceuticals's contingent consideration fair value adjustments?
Over 2 years (2022 to 2024), Cumberland Pharmaceuticals's contingent consideration fair value adjustments has grown at a -16.4% compound annual growth rate (CAGR), from -$2.09M to -$1.46M.